USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR … – GlobeNewswire (press release)
|
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR …
GlobeNewswire (press release) “This is the fourth time that our US Patent for Production of Allogeneic TCR-Deficient CAR–T cells is challenged and each time, the USPTO has been favorable to Celyad. This patent is key for the players that are developing in the US allogeneic CAR–T … |
MIT Technology Review |
CRISPR May Speed Pig-to-Human Transplants
MIT Technology Review The plan, says the company, is to use the gene-editing method known as CRISPR to introduce extensive DNA modifications into pigs as a way of humanizing their organs so they won’t get rejected if transferred into a person. (The back of the T-shirt reads … |
Business Insider |
A startup cofounded by a 30-year-old just got $38 million to revolutionize the way we transplant organs
Business Insider Egenesis, a startup that’s using the gene-editing tool CRISPR to make pig organs viable for transplants into people, just raised $38 million. The company, which launched back in 2015 and is co-founded by Harvard geneticist George Church and 30-year old … |